3
|
Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Dockter T, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Collins JM, Streicher H, Hawse JR, Haddad TC, Erlichman C, Ames MM, Ingle JN. Abstract PD2-03: Final results of a first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-Endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-pd2-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: AI's are more effective than TAM in ER+ breast cancer. In AI refractory MBC, the response rate to TAM is 0% (Osborne 2011). Z-Endx is an active metabolite of TAM and among TAM treated women in the adjuvant and metastatic settings, reduced CYP2D6 metabolism and low Endx concentrations (Css <20 nM) have been associated with increased likelihood of disease recurrence. Preclinical studies have demonstrated greater Z-Endx exposure and anti-tumor activity with oral Z-Endx compared to equivalent doses of oral TAM (Reid 2014)
Methods: We conducted a phase I trial to determine the maximum-tolerated dose (MTD) and evaluate the toxicities, clinical activity, and pharmacokinetics (PK) of Z-Endx in patients (pts) with ER+, AI refractory MBC. Unlimited prior endocrine regimens were allowed. An accelerated titration schedule was applied (2 pts/dose level) until moderate toxicity or DLT, followed by a 3+3 design and then to expansion cohorts (40, 80, and 100 mg/day). Z-Endx was administered orally once daily (28 day cycle). Eye exams were performed at baseline, and end of cycles 2 and 6. PK was performed during cycle 1 and prior to subsequent cycles. For pts in the expansion cohorts, tumor biopsies were obtained at baseline for DNA sequencing (Foundation Medicine). Plasma cholesterol levels were obtained at baseline and after 1 cycle.
Results: From March 2011 to Dec 2014, 41 pts (38 evaluable), median age 60, received Z-Endx once daily encompassing 7 dose levels (20-160 mg/daily). The median number of prior hormonal regimens was 2 and 3 for the dose escalation and expansion cohorts, respectively. Dose escalation was stopped at 160 mg/day given MTD not reached and attainment of mean Endx Css of 3.6 uM. Cycle 1 DLT (PE) was observed in one patient (60 mg). No eye toxicity was observed. PK demonstrated mean Endx Css of > 1 uM at all dose levels ≥ 40 mg/day. Antitumor activity was observed at multiple dose levels including 3 confirmed partial responses and an additional 7 with stable disease for ≥6 cycles. Of these 10 pts, 9 had prior progression on both AI and fulvestrant and 3 additionally on TAM. After 1 cycle, total and LDL cholesterol decreased > 20 points in 54% and 40% of pts, respectively. Tumor sequencing in the expansion cohorts (n=14) did not identify ESR1 mutations; however, ESR1 amplification was identified in 1 pt with prolonged stable disease (>200 days). Of 6 pts with rapid progression (≤2 cycles), 4/6 had either CCND1 amplification (n=1) or at least one of the following activating mutations: ERBB2 L755S (n=1), AKT1 E17K (n=1), MTOR E1799K (n=1).
Conclusions: The direct administration of Z-END provides substantial drug exposure, acceptable toxicity, and "proof of principle" antitumor activity in endocrine resistant MBC. While the MTD was not determined, the goal of achieving Endx Css concentrations of > 1 uM was achieved. Tumor sequencing identified pts with predicted and confirmed endocrine resistance. A randomized phase II comparing endoxifen (80 mg/day) with TAM in AI refractory MBC was recently activated (NCT02311933). Supported in part by CA 133049, CA186686, CA15083, CA116201, and CA15083.
Citation Format: Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Dockter T, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Collins JM, Streicher H, Hawse JR, Haddad TC, Erlichman C, Ames MM, Ingle JN. Final results of a first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-Endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr PD2-03.
Collapse
Affiliation(s)
- MP Goetz
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - VJ Suman
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - JM Reid
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - DW Northfelt
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - MA Mahr
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - T Dockter
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - M Kuffel
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - SA Buhrow
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - SL Safgren
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - RM McGovern
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - JM Collins
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - H Streicher
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - JR Hawse
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - TC Haddad
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - C Erlichman
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - MM Ames
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - JN Ingle
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| |
Collapse
|
4
|
Knutson KL, Kalli KR, Block MS, Hobday TJ, Padley DJ, Erskine CL, Dockter T, Suman VJ, Wilson G, Degnim AC. Abstract P2-11-02: Robust generation of T cell immunity to HER2 in HER2+ breast cancer patients with a degenerate subdominant HLA-DR epitope vaccine. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-11-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Recent studies have indicated that vaccination can protect against cancer development. One key aspect of developing vaccines is circumventing peripheral tolerance by identifying subdominant epitopes that are unique to the deregulated tumor microenvironment. While existing subdominant epitope vaccines are showing efficacy in preventing cancer, these vaccines are applicable only for subsets of patients with specific HLA subtypes. Therefore, we recently developed a degenerate HER2 subdominant epitope-based vaccine that should be useful in approximately 85% of all patients. The vaccine consists of a pool of four HLA-DR-restricted 15-amino acid epitopes (p59, p88, p422, and p885) that are naturally processed and are designed to elicit helper T cell immunity, the cornerstone of immune surveillance. Here we present Phase I trial results of this multi-peptide HER2 vaccine.
Methods: Eligible women had HER2+ breast cancer (Stages II-III) and had completed standard treatment (i.e. surgery, chemotherapy, and trastuzumab) at least 90 days prior to enrollment and were rendered disease free. Vaccine included the above epitope pool along with adjuvant GM-CSF. Patients were vaccinated six times over six months and were monitored for toxicity at each visit. Peripheral blood samples were collected for immune responses evaluating for T cell and antibody immunity. Endpoints were safety and immunogenicity leading to the development CD4 helper T cells that recognized naturally-processed HER2.
Results: Twenty-two subjects (age 33 to 69 years) were enrolled. At the present analysis, 21 have completed all 6 vaccination cycles; one patient withdrew after developing a grade 1 injection site reaction during the first vaccination cycle. Twenty patients have had LVEF measured after vaccination; only 2 patients had an LVEF drop of 10% or more but remained in the normal LEVF range. One severe toxicity was reported: a grade 3 INR increase considered unrelated to treatment. Mild to moderate (grade 1-2) toxicities included injection site reactions, fatigue, and white blood cell count decreases. All patients were alive at analysis and only one experienced a recurrence (median follow-up 507 days, range 22 – 844). Twenty patients have had immune response assessments. Vaccine induced T cell immunity was observed in 94% of patients to p59, in 94% of patients to p88, in 82% of patients to p422, and in 74% of patients to p885. Importantly, T cell immunity to naturally processed HER2 proteins occurred in 94% of patients. The mean number of T cells specific for each peptide, post vaccination, ranged from 349–528 T cells per million peripheral blood mononuclear cells (PBMCs). The mean number of T cells specific for whole HER2 protein was 783 T cells per million PBMCs compared to a mean of 898 T cells/million PBMCs specific for the foreign tetanus toxin. In contrast to T cell responses, modestly increased antibody immunity to HER2 occurred in 35% of patients, consistent with the T cell-inducing design of the vaccine.
Conclusion: Our results show that it is possible to develop vaccines with broad HLA coverage that circumvent natural tolerance and induce tumor antigen-specific immunity in the vast majority of patients.
Citation Format: Knutson KL, Kalli KR, Block MS, Hobday TJ, Padley DJ, Erskine CL, Dockter T, Suman VJ, Wilson G, Degnim AC. Robust generation of T cell immunity to HER2 in HER2+ breast cancer patients with a degenerate subdominant HLA-DR epitope vaccine. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-11-02.
Collapse
Affiliation(s)
- KL Knutson
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - KR Kalli
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - MS Block
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - TJ Hobday
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - DJ Padley
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - CL Erskine
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - T Dockter
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - VJ Suman
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - G Wilson
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - AC Degnim
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| |
Collapse
|